Latest Recruitment News

Middle Island Resources has launched a major 2026 exploration campaign at its Bobija Project in Serbia, initiating Phase 2 drilling and extensive soil sampling to expand on promising late 2025 results.

WhiteHawk Limited is realigning its leadership with an Australian-based Chair and CEO to capitalise on growing cybersecurity demands in the Asia Pacific region, while maintaining a strong foothold in the US market.

Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.

BlinkLab has enrolled its first participant in the pivotal FDA 510(k) validation study for its autism diagnostic aid, BlinkLab Dx1, aiming for regulatory submission by the end of 2026.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Xref Limited has launched strategic integrations with leading HR platforms Teamtailor and HiBob, aiming to accelerate its transition to a high-margin, API-driven revenue model and expand its global footprint.

After an 18-month trading suspension, Lithium Energy Limited has resumed ASX trading, unveiling a diversified portfolio including new gold-copper and lithium brine projects alongside a strategic graphite acquisition.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

Aguia Resources has secured key mining concessions in Brazil, setting the stage for operational licensing and commissioning of its Tres Estradas phosphate mine by April 2026.